(VIANEWS) – Viper Energy Partners LP (VNOM), Zynex (ZYXI), NXP Semiconductors (NXPI) are the highest sales growth and return on equity stocks on this list.

Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?

1. Viper Energy Partners LP (VNOM)

72.4% sales growth and 17.63% return on equity

Viper Energy Partners LP acquires and owns natural gas properties throughout North America.

Viper Energy Partners LP’s sales growth this year is anticipated to be 65.2% and a negative 5.8% for next year.

Year-on-year quarterly revenue growth grew by 108.6%, now sitting on 578.22M for the twelve trailing months.

Volume

Today’s last reported volume for Viper Energy Partners LP is 282375 which is 53.25% below its average volume of 604021.

Viper Energy Partners LP’s sales growth for the next quarter is 72.4%. The company’s growth estimates for the ongoing quarter and the next is a negative 0% and negative 0%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 17.63%.

Volatility

Viper Energy Partners LP’s last day, last week, and last month’s current intraday variation average was 2.01%, 2.65%, and 4.22%, respectively.

Viper Energy Partners LP’s highest amplitude of average volatility was 1.88% (day), 3.79% (last week), and 5.61% (last month), respectively.

Viper Energy Partners LP’s Stock Yearly Top and Bottom Value

Viper Energy Partners LP’s stock is valued at $25.41 at 01:22 EST, way under its 52-week high of $35.85 and way above its 52-week low of $15.98.

Viper Energy Partners LP’s Moving Average

Viper Energy Partners LP’s value is way below its 50-day moving average of $29.53 and under its 200-day moving average of $26.63.

2. Zynex (ZYXI)

20.7% sales growth and 29.08% return on equity

Zynex, Inc., via its subsidiaries, designs, produces, and markets medical products to treat acute and chronic pain. It also activates and exercises muscles for rehabilitation purposes using electrical stimulation.

Zynex’s sales growth this year is expected to be 22.1% and 24.5% for next year.

Year-on-year quarterly revenue growth grew by 28.8%, now sitting on 137.26M for the twelve trailing months.

Volume

Today’s last reported volume for Zynex is 242439 which is 45.13% below its average volume of 441919.

Zynex’s sales growth for the next quarter is 20.7%. The company’s growth estimates for the current quarter and the next is a negative 0% and negative -20%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 29.08%.

Volatility

Zynex’s last day, last week, and last month’s current intraday variation average was 0.13%, 1.07%, and 3.90%, respectively.

Zynex’s highest amplitude of average volatility was 7.44% (day), 5.52% (last week), and 7.58% (last month), respectively.

Zynex’s Stock Yearly Top and Bottom Value

Zynex’s stock is valued at $7.62 at 01:22 EST, way under its 52-week high of $16.26 and way higher than its 52-week low of $4.97.

Zynex’s Moving Average

Zynex’s value is higher than its 50-day moving average of $7.50 and below its 200-day moving average of $8.37.

3. NXP Semiconductors (NXPI)

17.5% sales growth and 23.94% return on equity

NXP Semiconductors N.V. provides a variety of semiconductor products.

NXP Semiconductors’s sales growth this year is expected to be 18.5% and 5.4% for next year.

Year-on-year quarterly revenue growth grew by 21.2%, now sitting on 11.06B for the twelve trailing months.

Volume

Today’s last reported volume for NXP Semiconductors is 2039110 which is 35.03% below its average volume of 3138800.

NXP Semiconductors’s sales growth is a negative 0% for the present quarter and 17.5% for the next. The company’s growth estimates for the present quarter and the next is 38.9% and 23.2%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 23.94%.

Volatility

NXP Semiconductors’s last day, last week, and last month’s current intraday variation average was 0.58%, 2.82%, and 2.06%, respectively.

NXP Semiconductors’s highest amplitude of average volatility was 2.02% (day), 3.73% (last week), and 3.63% (last month), respectively.

NXP Semiconductors’s Stock Yearly Top and Bottom Value

NXP Semiconductors’s stock is valued at $173.59 at 01:22 EST, way below its 52-week high of $239.91 and way above its 52-week low of $140.33.

NXP Semiconductors’s Moving Average

NXP Semiconductors’s worth is higher than its 50-day moving average of $169.05 and under its 200-day moving average of $192.12.

4. Vir Biotechnology (VIR)

8% sales growth and 49.2% return on equity

Vir Biotechnology, Inc., a company in clinical immunology, creates treatments to prevent and treat serious infections.

Vir Biotechnology’s sales growth this year is expected to be 39.2% and a negative 70.8% for next year.

Year-on-year quarterly revenue growth grew by 46771.2%, now sitting on 1.1B for the twelve trailing months.

Volume

Today’s last reported volume for Vir Biotechnology is 155933 which is 84.85% below its average volume of 1029260.

Vir Biotechnology’s sales growth is a negative 0% for the ongoing quarter and 8% for the next. The company’s growth estimates for the current quarter and the next is a negative 60.9% and negative -172%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 49.2%.

Volatility

Vir Biotechnology’s last day, last week, and last month’s current intraday variation average was 2.97%, 4.67%, and 3.46%, respectively.

Vir Biotechnology’s highest amplitude of average volatility was 4.23% (day), 6.11% (last week), and 6.12% (last month), respectively.

Vir Biotechnology’s Stock Yearly Top and Bottom Value

Vir Biotechnology’s stock is valued at $30.01 at 01:23 EST, way under its 52-week high of $58.00 and way higher than its 52-week low of $18.21.

Vir Biotechnology’s Moving Average

Vir Biotechnology’s worth is way above its 50-day moving average of $25.30 and under its 200-day moving average of $30.68.

LEAVE A REPLY

Please enter your comment!
Please enter your name here